Ozanimod (RPC1063) Potentially Confers Neuroprotective Benefit through Modulation of S1P1R on Astrocytes

被引：0
|
作者：
Meadows, Kristen R. Taylor [1 ]
Akhtar, Mohd Waseem [1 ]
Villescaz, Christiane [1 ]
Clemons, Bryan [1 ]
Lopez, Carlos [1 ]
Sawa-Ballweber, Samantha [1 ]
Dines, Kevin [1 ]
Opiteck, Gregory J. [1 ]
Scott, Fiona L. [1 ]
Selkirk, Julie V. [1 ]
机构：
[1] Receptos, San Diego, CA USA
来源：
MULTIPLE SCLEROSIS JOURNAL | 2018年 / 24卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P160
引用
收藏
页码：82 / 83
页数：2
相关论文
共 50 条
  • [1] Ozanimod (RPC1063) is potentially neuroprotective through direct CNS effects
    Meadows, K. R. Taylor
    Selkirk, J. V.
    Akhtar, M. W.
    Hutton, C.
    Opiteck, G. J.
    Scott, F. L.
    MULTIPLE SCLEROSIS JOURNAL, 2017, 23 : 624 - 624
  • [2] Discovery of ozanimod (RPC1063): A S1P1R and S1P5R selective agonist for the treatment of autoimmune disease
    Tamiya, Junko
    Martinborough, Esther
    Yeager, Adam
    Huang, Liming
    Enugurthi, Brahmachary
    Moorjani, Manisha
    Boehm, Marcus
    Scott, Fiona
    Clemons, Bryan
    Brooks, Jennifer
    Powell, Rachel
    Dedman, Harry
    Desale, Hans
    Reinhart, Gregory
    Timony, Gregg
    Peach, Robert
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2016, 252
  • [3] The Preclinical Safety Profile of RPC1063, a Selective and Potent Sphingosine 1-Phosphate 1 Receptor (S1P1R) Agonist
    Timony, Gregg
    Brooks, Jennifer
    Powell, Rachel
    Dedman, Harry
    Scott, Fiona
    Martinborough, Esther
    Boehm, Marcus
    Rosen, Hugh
    Peach, Robert
    NEUROLOGY, 2013, 80
  • [4] Ozanimod (RPC1063) is potentially neuroprotective through direct activity on Th1 and Th17 T cell expansion and migration, monocyte migration and microglia expansion
    Guimond, D.
    Boyett, M.
    Lopez, C.
    Sawa-Ballweber, S.
    Villescaz, C.
    Dines, K.
    Opiteck, G. J.
    Scott, F. L.
    Meadows, K. R. Taylor
    MULTIPLE SCLEROSIS JOURNAL, 2017, 23 : 623 - 623
  • [5] Results of a Safety and Tolerability Study of Rpc1063, a Novel Orally Administered Sphingosine-1-Phosphate Receptor 1 (S1p1r) Agonist, in Healthy Adult Volunteers
    Olson, Allan
    Timony, Gregg
    Hartung, Jeffrey P.
    Smith, Heather
    Peach, Robert J.
    Rosen, Hugh
    Pan, Christine
    Brooks, Jennifer
    Boehm, Marcus
    Gujrathi, Sheila
    GASTROENTEROLOGY, 2013, 144 (05) : S234 - S234
  • [6] Rpc1063 Is a Potent S1p1r Agonist With Efficacy in the Samp1yitfc Ileitis Model: New Evidence for Dysregulation of S1p Metabolism in Preclinical Models and Patients With Inflammatory Bowel Disease
    Scott, Fiona L.
    Behrens, En-hui H.
    Clemons, Bryan
    Gonzalez-Cabrera, Pedro
    Bamias, Giorgos
    Rosen, Hugh
    Peach, Robert J.
    Rivera-Nieves, Jesus
    GASTROENTEROLOGY, 2013, 144 (05) : S807 - S807
  • [7] Favourable S1P1R/5R Selectivity Profile of Ozanimod Confers Safety Benefit Relating to S1P3R-Mediated Pro-Fibrotic Changes in Fibroblasts
    Clemons, Bryan
    Bain, Gretchen
    Lai, Andiliy
    Santini, Angelina M.
    Goulet, Lance
    Boyett, Megan
    Roberts, Edward
    Rosen, Hugh
    Opiteck, Gregory J.
    Scott, Fiona L.
    Taylor, Kristen R.
    MULTIPLE SCLEROSIS JOURNAL, 2018, 24 : 39 - 39
  • [8] Ozanimod (RPC1063) is a potent sphingosine-1-phosphate receptor-1 (S1P1) and receptor-5 (S1P5) agonist with autoimmune disease-modifying activity
    Scott, F. L.
    Clemons, B.
    Brooks, J.
    Brahmachary, E.
    Powell, R.
    Dedman, H.
    Desale, H. G.
    Timony, G. A.
    Martinborough, E.
    Rosen, H.
    Roberts, E.
    Boehm, M. F.
    Peach, R. J.
    BRITISH JOURNAL OF PHARMACOLOGY, 2016, 173 (11) : 1778 - 1792
  • [9] Safety and tolerability of orally administered RPC1063, a novel S1P1 receptor agonist, in healthy adult volunteers
    Hartung, J.
    Peach, R.
    Boehm, M.
    Rosen, H.
    Smith, H.
    Pan, C.
    Brooks, J.
    Timony, G.
    Gujrathi, S.
    MULTIPLE SCLEROSIS JOURNAL, 2012, 18 : 186 - 186
  • [10] Ozanimod (RPC1063), a selective S1PR1 and S1PR5 modulator, reduces chronic inflammation and alleviates kidney pathology in murine systemic lupus erythematosus
    Meadows, Kristen R. Taylor
    Steinberg, Marcos W.
    Clemons, Bryan
    Stokes, Matthew E.
    Opiteck, Gregory J.
    Peach, Robert
    Scott, Fiona L.
    PLOS ONE, 2018, 13 (04):
12345